Historical shareholding details of
GAUTAM RASIKLAL ASHRA
holdings in Bliss GVS Pharma Ltd. (BLISSGVS)
Quarterly changes of
GAUTAM RASIKLAL ASHRA
shareholding in Bliss GVS Pharma Ltd.
over the previous
quarters
Quarter
|
Name |
Total no. shares held |
Percent Holding |
Pledged
|
Locked
|
shares
|
%
|
shares
|
%
|
Sep 2025
|
Gautam Rasiklal Ashra
|
2,981,571
|
2.82%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Jun 2025
|
Gautam Rasiklal Ashra
|
2,981,571
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Mar 2025
|
Gautam Rasiklal Ashra
|
2,981,571
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Dec 2024
|
Gautam Rasiklal Ashra
|
2,981,571
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Sep 2024
|
Gautam Rasiklal Ashra
|
2,951,571
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Jun 2024
|
Gautam Rasiklal Ashra
|
2,966,571
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Mar 2024
|
Gautam Rasiklal Ashra
|
2,946,302
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Dec 2023
|
Gautam Rasiklal Ashra
|
2,946,302
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Sep 2023
|
Gautam Rasiklal Ashra
|
2,946,302
|
2.82%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Jun 2023
|
Gautam Rasiklal Ashra
|
2,946,302
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Mar 2023
|
Gautam Rasiklal Ashra
|
2,946,302
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Dec 2022
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.80%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Sep 2022
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Jun 2022
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Mar 2022
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Dec 2021
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.81%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Sep 2021
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.82%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Jun 2021
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.82%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Mar 2021
|
Gautam Rasiklal Ashra
|
2,920,802
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
|
|
|
Dec 2020
|
Gautam Rasiklal Ashra
|
2,918,302
|
2.83%
|
0
|
0.00%
|
0
|
0.00%
|
View all shareholdings details of Bliss GVS Pharma Ltd.